Medicare Launches a $50 Monthly Weight-Loss Drug Option — Who Can Get It

For more than 20 years, Medicare has been prohibited from covering drugs used only for weight loss. That policy is now easing, at least for a limited period, through a new program that may sharply reduce the cost of popular GLP-1 medications.

The Medicare GLP-1 Bridge program started on July 1, 2026, and is scheduled to continue through December 31, 2027. During that time, certain Medicare beneficiaries can obtain select GLP-1 drugs for a flat $50 copayment for a one-month supply.

What the Bridge program includes

The program is available to Medicare beneficiaries with qualifying drug coverage, including people with standalone Part D plans and those enrolled in Medicare Advantage plans that include prescription drug benefits.

Participants can receive a limited set of GLP-1 medicines, including Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet).

These medications are used for weight management and may improve health. Still, the Medicare GLP-1 Bridge program does not apply to people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Medicare says Part D coverage may be available for GLP-1 drugs when prescribed for those conditions.

Who is eligible

Eligibility is divided into three tiers, based mainly on body mass index, or BMI, and certain health conditions.

Tier 1 includes adults with a BMI of 35 or higher. No other qualifying condition is needed.

Tier 2 applies to adults with a BMI of 30 or higher who also have at least one of the following:

• Diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF)
• Uncontrolled high blood pressure
• Chronic kidney disease stage 3a or worse

Tier 3 covers adults with a BMI of 27 or higher who also have at least one of these conditions:

• Prediabetes
• A prior heart attack or stroke
• Symptomatic peripheral artery disease

Applicants must be at least 18 years old. They also need qualifying Medicare drug coverage, and a health care provider must certify that the GLP-1 medication is being used as part of a lifestyle program centered on diet and exercise.

People are not eligible for the Bridge program if they already receive a GLP-1 drug through Medicare Part D or if they have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. In those cases, Part D may cover the medication instead.

How to use the benefit

If you qualify, your doctor or another health care provider sends a prescription for a covered GLP-1 drug to your pharmacy. When needed, the provider must also complete prior authorization.

Your provider must certify that the drug is part of a lifestyle program focused on diet and exercise. After Medicare approves the coverage, you will receive a letter confirming that the medication is covered under the Medicare GLP-1 Bridge program.

What the $50 copay means

The $50 monthly copayment is one of the most notable parts of the program, but it comes with several limits.

That amount covers one month of medication, typically 28 or 30 days depending on the drug. It does not count toward a beneficiary’s Part D deductible or annual out-of-pocket limit, and it will not appear on a Part D Explanation of Benefits or Medicare Summary Notice.

The copayment also cannot be reduced through Extra Help or spread out over several months through the Medicare Prescription Payment Plan.

Important details to keep in mind

Several other rules may affect how helpful the program is for different households.

One major issue involves the low-income subsidy known as Extra Help. Beneficiaries who qualify for Extra Help usually get assistance with prescription drug costs under Part D, but that help cannot be applied to medications obtained through the GLP-1 Bridge program.

As a result, some lower-income beneficiaries may not save more than the $50 monthly price, even if they normally pay less for other prescriptions.

Timing also matters. Because the program is temporary, it is set to end on December 31, 2027. Coverage is not guaranteed after that point, so patients who use the Bridge program may need to look for other coverage options later.

How Medicare is changing its approach

The Bridge program marks a notable shift in how Medicare treats weight-loss drugs.

In the past, coverage has generally been limited to treatments linked directly to specific medical conditions, such as diabetes. Medications prescribed mainly for weight loss have largely been excluded, even as obesity-related health problems have become more widespread.

By allowing limited access to GLP-1 drugs, the program suggests Medicare is placing more emphasis on the role these treatments can play in helping prevent more serious and costly health issues.

What it means for medical costs

For eligible beneficiaries, the program offers a $50 copayment for a one-month supply of a covered GLP-1 drug. Many of these medications have remained out of reach for Medicare recipients because of high out-of-pocket costs, so a fixed monthly price could make them much more affordable in the short term.

Even so, the program’s structure means it does not lower overall Medicare drug spending in the same way standard coverage does. And because it is temporary, it may not serve as a long-term answer for people who depend on these medications.

Beneficiaries who think they may qualify should speak with their health care provider first. They can also visit Medicare.gov/glp1bridge or call 1-800-MEDICARE for more information and next steps.

The takeaway

The Medicare GLP-1 Bridge program is a significant, though temporary, change in coverage for weight-loss medications. Eligible beneficiaries can get drugs such as Wegovy and Zepbound for $50 a month, which could greatly reduce out-of-pocket costs.

Still, the program includes important restrictions and will not last indefinitely, so understanding the details is essential.